Eads & Heald Wealth Management Buys New Stake in Gilead Sciences, Inc. $GILD

Eads & Heald Wealth Management purchased a new stake in Gilead Sciences, Inc. (NASDAQ:GILD) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 6,128 shares of the biopharmaceutical company’s stock, valued at approximately $854,000.

A number of other institutional investors have also modified their holdings of the stock. Norges Bank purchased a new position in Gilead Sciences during the fourth quarter valued at approximately $2,617,152,000. Boston Partners acquired a new position in Gilead Sciences in the fourth quarter valued at approximately $517,808,000. Massachusetts Financial Services Co. MA boosted its position in Gilead Sciences by 3,763.8% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 4,223,304 shares of the biopharmaceutical company’s stock worth $518,368,000 after purchasing an additional 4,113,999 shares in the last quarter. Bank of America Corp DE grew its stake in shares of Gilead Sciences by 15.2% during the 4th quarter. Bank of America Corp DE now owns 23,121,620 shares of the biopharmaceutical company’s stock worth $2,837,948,000 after purchasing an additional 3,046,688 shares during the period. Finally, Vanguard Group Inc. grew its stake in shares of Gilead Sciences by 1.8% during the 4th quarter. Vanguard Group Inc. now owns 121,097,336 shares of the biopharmaceutical company’s stock worth $14,863,487,000 after purchasing an additional 2,113,692 shares during the period. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences Stock Performance

NASDAQ:GILD opened at $136.36 on Wednesday. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.77 and a current ratio of 1.97. The stock has a market capitalization of $169.30 billion, a PE ratio of 18.58 and a beta of 0.32. Gilead Sciences, Inc. has a fifty-two week low of $107.75 and a fifty-two week high of $157.29. The company has a fifty day moving average of $129.48 and a two-hundred day moving average of $134.82.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 EPS for the quarter, topping analysts’ consensus estimates of $1.91 by $0.12. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The business had revenue of $6.96 billion during the quarter, compared to analysts’ expectations of $6.91 billion. During the same quarter in the previous year, the company earned $1.81 earnings per share. The company’s quarterly revenue was up 4.4% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. As a group, research analysts forecast that Gilead Sciences, Inc. will post -0.8 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, June 29th. Shareholders of record on Monday, June 15th were issued a dividend of $0.82 per share. The ex-dividend date of this dividend was Monday, June 15th. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.4%. Gilead Sciences’s dividend payout ratio is presently 44.69%.

Gilead Sciences News Summary

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead won FDA approval to expand Trodelvy into first-line metastatic triple-negative breast cancer, a meaningful label expansion that could broaden the drug’s market opportunity and strengthen the company’s oncology growth story. Will the Label Expansion of Trodelvy Strengthen GILD’s Oncology Portfolio?
• Positive Sentiment: HSBC upgraded Gilead to Buy and raised its price target to $155, citing continued upside from long-acting HIV treatments and oncology assets. Generic Fears Overdone? Gilead Stock Has More Room to Run, Analyst Says
• Positive Sentiment: Cantor Fitzgerald reaffirmed an Overweight rating and kept a $155 price target, signaling confidence in Gilead’s earnings and pipeline outlook. Read More
• Positive Sentiment: Broader biotech sentiment also looked favorable after Jim Cramer called biotech “the hottest group in the market” and said a wave of M&A could be coming, which can lift names like Gilead. Jim Cramer Calls Biotech “The Hottest Group in the Market” as He Predicts “Deals Are Going to Be Flooding the Market”
• Neutral Sentiment: Royal Bank of Canada trimmed its price target to $120 from $122 and kept a Sector Perform rating, which is a modestly cautious view but not a major negative catalyst. Read More
• Neutral Sentiment: Gilead’s stock also drew attention from market commentary noting the shares had run up sharply and were trading well above GuruFocus’ GF Value estimate, suggesting valuation may be getting stretched. A Look at Gilead Sciences Inc (GILD) After 5.2% Gain — GF Value $96.06 vs Price $136.36

Insider Transactions at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 3,000 shares of the business’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $125.40, for a total transaction of $376,200.00. Following the completion of the sale, the chief financial officer directly owned 171,646 shares in the company, valued at approximately $21,524,408.40. The trade was a 1.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 3,000 shares of the firm’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $123.92, for a total value of $371,760.00. Following the completion of the transaction, the insider owned 124,234 shares in the company, valued at $15,395,077.28. The trade was a 2.36% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 83,000 shares of company stock valued at $10,824,500 over the last ninety days. Insiders own 0.30% of the company’s stock.

Analysts Set New Price Targets

GILD has been the subject of several analyst reports. The Goldman Sachs Group boosted their target price on shares of Gilead Sciences from $125.00 to $130.00 and gave the company a “neutral” rating in a research note on Friday, April 17th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $155.00 price objective on shares of Gilead Sciences in a report on Monday. Royal Bank Of Canada decreased their price objective on shares of Gilead Sciences from $122.00 to $120.00 and set a “sector perform” rating for the company in a research report on Tuesday. Citigroup increased their target price on shares of Gilead Sciences from $156.00 to $165.00 and gave the stock a “buy” rating in a research note on Monday, April 13th. Finally, Truist Financial dropped their target price on Gilead Sciences from $157.00 to $156.00 and set a “buy” rating on the stock in a research report on Tuesday. Twenty-six equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $159.11.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.